Patents Issued in January 19, 2017
  • Publication number: 20170014368
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Application
    Filed: July 19, 2016
    Publication date: January 19, 2017
    Inventors: Krzysztof Palczewski, Matthew Batten
  • Publication number: 20170014369
    Abstract: There are provided compositions comprising Such compositions can also further comprise various components such as lipids (for example fatty acids, esters thereof or derivatives thereof). Such compositions can be used for example in methods for treating an inflammatory diseases chosen from inflammatory bowel diseases, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, acute lung injury, bronchopulmonary dysplasia, cystic fibrosis, bronchitis, bronchiolitis, arthritis, osteoarthritis, ankylosing spondylitis and rheumatism.
    Type: Application
    Filed: September 30, 2016
    Publication date: January 19, 2017
    Inventor: Samuel FORTIN
  • Publication number: 20170014370
    Abstract: This invention is directed to substituted acylanilide compounds and uses thereof in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.
    Type: Application
    Filed: May 12, 2016
    Publication date: January 19, 2017
    Inventors: James T. Dalton, Duane D. Miller, Ramesh Narayanan, Thamarai Ponnusamy
  • Publication number: 20170014371
    Abstract: This invention is directed to substituted acylanilide compounds and uses thereof in treating muscular dystrophies such as Duchenne muscular dystrophy and Becker muscular dystrophy and in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.
    Type: Application
    Filed: June 23, 2016
    Publication date: January 19, 2017
    Inventors: James T. DALTON, Thamarai PONNUSAMY, Ramesh NARAYANAN
  • Publication number: 20170014372
    Abstract: Angiogenesis inhibitory drug combination obtained according to a specific algorithm, preferably a FSC, in which an initial combination of drugs is iteratively adjusted. The drug combination according to the invention may advantageously comprise a RAPTA-C compound. In a more specific case the combination comprises RAPTA-C and eriotinib.
    Type: Application
    Filed: March 12, 2015
    Publication date: January 19, 2017
    Inventors: Patrycja Nowak-Sliwinska, Paul Dyson, Arjan Griffioen, Andrea Weiss, Hubert Van den Bergh, Xianting Ding
  • Publication number: 20170014373
    Abstract: The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.
    Type: Application
    Filed: June 15, 2016
    Publication date: January 19, 2017
    Inventors: Neil P. DESAI, Patrick SOON-SHIONG
  • Publication number: 20170014374
    Abstract: The present invention provides compositions that are substantially niacin free for treating dyslipidemia and/or inflammation in a subject. Compositions of the invention include a therapeutically effective amount of a mixture phytosomes obtained from quercetin and at least one other phytosome obtained from the group consisting of curcurmin, green tea, and a combination thereof. The present invention also provides a method for treating dyslipidemia and/or inflammation in a subject.
    Type: Application
    Filed: July 13, 2015
    Publication date: January 19, 2017
    Applicant: THORNE RESEARCH, INC.
    Inventors: Bodi Zhang, Michael A Schmidt, Mark Houston, Robert Rountree
  • Publication number: 20170014375
    Abstract: The present invention provides a compound of formula (I) as a SERCA inhibitor for treating cancers, a pharmaceutical composition comprising said compound, and methods of using said compound for treating cancers and/or inducing cell death in cells of said cancers. Said cancers include but not limited to cervical, lung, liver, breast, and prostate cancer. Said cancers also include drug-resistant and/or apoptosis-resistant cancers such as isogenic drug-resistant colon cancer. The subject being administered with said compound or the composition comprising thereof can be human or animal subject. Said methods for treating cancers and/or inducing cell death can be a targeting treatment for certain cancers.
    Type: Application
    Filed: July 14, 2015
    Publication date: January 19, 2017
    Inventors: Kam Wai WONG, Yuen Kwan LAW, Liang LIU, Su-Wei XU
  • Publication number: 20170014376
    Abstract: A method and compositions for treating cancer is described using at least two epigenetic modifiers. In various embodiments, hyperbaric oxygen therapy and glycolytic inhibition therapy are used as well.
    Type: Application
    Filed: March 21, 2016
    Publication date: January 19, 2017
    Inventor: Mohammad Amin Nezami
  • Publication number: 20170014377
    Abstract: The invention relates to a complex of an anthocyanidin and a methylated ?-cyclodextrin which can be formulated as an aqueous solution and as a solid, and to a process for the preparation of such a complex. Complexes according to the invention are storage-stable and can be readily formulated in aqueous solution.
    Type: Application
    Filed: February 26, 2015
    Publication date: January 19, 2017
    Inventors: Norbert Roewer, Jens Broscheit
  • Publication number: 20170014378
    Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:
    Type: Application
    Filed: July 21, 2016
    Publication date: January 19, 2017
    Inventors: Deborah Hung, Sarah Stanley, Tomohiko Kawate, Noriakie Iwase, Motohisa Shimizu
  • Publication number: 20170014379
    Abstract: The present invention relates to a pharmaceutical formulation comprising therapeutically effective amount of vildagliptin or pharmaceutically acceptable salt thereof and a diluent. Particularly, the ratio of vildagliptin to diluent is in the range of 0.04 to 0.24 (w/w).
    Type: Application
    Filed: March 5, 2015
    Publication date: January 19, 2017
    Inventors: Ali Turkyilmaz, Ali Hasan Turp, Mehtap Saydam, Onur Ulgen
  • Publication number: 20170014380
    Abstract: The present invention relates to a process for preparing a pharmaceutical composition of vildagliptin under oxygen free inert gas atmosphere. The present invention particularly relates to a pharmaceutical composition of vildagliptin obtained by the process which is stable to oxygen physiologically and chemically.
    Type: Application
    Filed: March 5, 2015
    Publication date: January 19, 2017
    Inventors: Ali Turkyilmaz, Gulay Yelken, Mehtap Saydam, Onur Ulgen
  • Publication number: 20170014381
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Application
    Filed: May 18, 2016
    Publication date: January 19, 2017
    Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doobs, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
  • Publication number: 20170014382
    Abstract: Disclosed herein are self-emulsifying compositions and formulations of Diindolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.
    Type: Application
    Filed: April 8, 2016
    Publication date: January 19, 2017
    Applicant: BioResponse, L.L.C.
    Inventors: Michael A. Zeligs, Irwin C. Jacobs
  • Publication number: 20170014383
    Abstract: The invention described herein provides a solid dispersion of Indirubin, a pharmaceutical composition comprising the solid dispersion of Indirubin, a process for preparing the solid dispersion and pharmaceutical composition, and a method of using the pharmaceutical composition.
    Type: Application
    Filed: June 20, 2016
    Publication date: January 19, 2017
    Applicant: Phosphorex, Inc.
    Inventor: Bin Wu
  • Publication number: 20170014384
    Abstract: A leukotriene C4 and D4 antagonist is used to inhibit tumor metastasis by acting to inhibit tumor cell adhesion to endothelial cells, therby preventing tumor cell extravasation.
    Type: Application
    Filed: February 16, 2016
    Publication date: January 19, 2017
    Inventor: Masako Nozaki
  • Publication number: 20170014385
    Abstract: The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor and their uses for the treatment and prophylaxis of visual hallucinations associated with Lewy Body dementia.
    Type: Application
    Filed: July 15, 2016
    Publication date: January 19, 2017
    Inventors: Lawrence Tim FRIEDHOFF, Shankar RAMASWAMY, Yandong WEN
  • Publication number: 20170014386
    Abstract: The present disclosure provides compositions and methods for treating multidrug-resistant nephrotic syndrome (MDR-NS) in pediatric subjects comprising atrasentan. Methods of reducing protenuria in a pediatric patient having MDR-NS are also provided.
    Type: Application
    Filed: July 15, 2016
    Publication date: January 19, 2017
    Inventors: John J. Brennan, Franz Schaefer, Melissa E. Wigderson
  • Publication number: 20170014387
    Abstract: The present disclosure is directed to generally methods for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a premenopausal or perimenopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. These methods may also be useful in post-menopausal woman.
    Type: Application
    Filed: April 26, 2016
    Publication date: January 19, 2017
    Inventor: Stephen Nigel Birrell
  • Publication number: 20170014388
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 16, 2016
    Publication date: January 19, 2017
    Applicant: NOVARTIS AG
    Inventors: Kamlesh Jagdis BALA, Andrew BREARLEY, James DALE, Anne-Marie EDWARDS, Mahbub AHMED, David PORTER, Robert Alexander PULZ, Lisa Ann ROONEY, David Andrew SANDHAM, Duncan SHAW, Nichola SMITH, Jessica Louise TAYLOR, Roger John TAYLOR, Thomas Josef Troxler, Joe WRIGGLESWORTH
  • Publication number: 20170014389
    Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
    Type: Application
    Filed: April 19, 2016
    Publication date: January 19, 2017
    Inventor: Alan B. Montgomery
  • Publication number: 20170014390
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Application
    Filed: March 23, 2016
    Publication date: January 19, 2017
    Applicant: MediciNova, Inc.
    Inventors: Michael E. KALAFER, Kenneth W. LOCKE, Kazuko MATSUDA, Richard E. GAMMANS
  • Publication number: 20170014391
    Abstract: The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of SGK1 are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of SGK1 inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, SGK1 inhibitors also have Glucocorticoid Receptor (GR) and/or Androgen Receptor (AR) inhibitory activity or are administered in conjunction with GR and/or AR inhibitors.
    Type: Application
    Filed: December 11, 2014
    Publication date: January 19, 2017
    Inventors: Vivek Arora, Charles L. Sawyers
  • Publication number: 20170014392
    Abstract: Methods of treating a developmental disorder such as Dravet syndrome by administering a pharmaceutical composition of gaboxadol or a pharmaceutically acceptable salt thereof are provided.
    Type: Application
    Filed: June 23, 2016
    Publication date: January 19, 2017
    Inventor: Matthew DURING
  • Publication number: 20170014393
    Abstract: Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder.
    Type: Application
    Filed: July 14, 2016
    Publication date: January 19, 2017
    Inventor: Matthew DURING
  • Publication number: 20170014394
    Abstract: The present invention relates to methods of treatment of hepatitis C using prasugrel. The methods of the present invention can be used in patients with hepatitis C administering prasugrel in combination with one or more anti-hepatitis C drugs.
    Type: Application
    Filed: July 18, 2016
    Publication date: January 19, 2017
    Inventors: Karl Roberts, Geena Malhotra, Dhiraj Abhyankar, Kalpana Joshi, Jeevan Ghosalkar
  • Publication number: 20170014395
    Abstract: An object of the present invention is to provide a novel endoparasite control agent as a parasiticide, an antiprotozoal or the like. Provided is an endoparasite control agent comprising a carboxamide derivative represented by the general formula (I): or a salt thereof as an active ingredient.
    Type: Application
    Filed: September 15, 2016
    Publication date: January 19, 2017
    Inventors: Kiyoshi Kita, Akiyuki Suwa, Masatsugu Oda, Koji Tanaka
  • Publication number: 20170014396
    Abstract: Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein.
    Type: Application
    Filed: March 13, 2015
    Publication date: January 19, 2017
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventor: Chong-Hui Gu
  • Publication number: 20170014397
    Abstract: Disclosed are methods and compositions for treating or preventing a disease or disorder responsive to a decrease in baseline mitochondrial iron in a subject in need thereof. The methods typically include administering a pharmaceutical composition comprising a mitochondrial permeable iron chelator to the subject.
    Type: Application
    Filed: July 13, 2016
    Publication date: January 19, 2017
    Applicant: Northwestern University
    Inventors: Hossein Ardehali, Hsiang-Chun Chang
  • Publication number: 20170014398
    Abstract: The present application relates to topical compositions. In particular, the present application relates to a topical composition comprising retinoid as active agent, and pharmaceutically acceptable excipient(s), and a process of preparing such compositions. Further, the present application relates to method of using topical compositions for the treatment of skin disorders such as acne, rosacea, psoriasis etc.
    Type: Application
    Filed: July 13, 2016
    Publication date: January 19, 2017
    Inventors: Sateesh Kandavilli, Franklin Okumu, Manish M. Banker, Sujit Kumar Dolai
  • Publication number: 20170014399
    Abstract: Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Application
    Filed: June 13, 2016
    Publication date: January 19, 2017
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • Publication number: 20170014400
    Abstract: The present invention provides a method of treating or preventing hyperlipidemia in a subject in need thereof. Such method includes, specifically, administrating to the subject a therapeutically effective amount of a caffeamide derivative. The present invention also provides a pharmaceutical composition containing, primarily, the caffeamide derivative. The method and pharmaceutical composition of the present invention can effectively and significantly lower the high-fat diet-induced body weight gain and absolute visceral fat weight as well as the concentration of triglycerides and free fatty acids in blood, and levels of total lipid and triacylglycerol in liver tissue. In addition, the caffeamide of the present invention also reduces size of adipocyte, hepatocellular ballooning phenomenon, and liver steatosis.
    Type: Application
    Filed: July 15, 2015
    Publication date: January 19, 2017
    Inventor: Chun-Ching Shih
  • Publication number: 20170014401
    Abstract: The present application relates to methods of treating, preventing, delaying the onset of, reducing the incidence of, or reducing the severity of fibrosis, obesity and conditions associated with post-menopausal obesity.
    Type: Application
    Filed: February 9, 2016
    Publication date: January 19, 2017
    Inventors: James T. Dalton, Ramesh Narayanan, Muralimohan Yepuru
  • Publication number: 20170014402
    Abstract: Provided herein are methods for treating cancer relating to inhibition of PI3K, as pharmaceutical compositions comprising a PI3K inhibitor and a PAK1 inhibitor.
    Type: Application
    Filed: January 8, 2014
    Publication date: January 19, 2017
    Inventors: Sandeep S. Dave, Katherine Walsh
  • Publication number: 20170014403
    Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
    Type: Application
    Filed: September 30, 2016
    Publication date: January 19, 2017
    Inventors: Serengulam V. Govindan, David M. Goldenberg
  • Publication number: 20170014404
    Abstract: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 19, 2017
    Inventors: Anthony A. McKinney, Gary D. Tollefson, Richard Soltero, Thea Elise Dunzo
  • Publication number: 20170014405
    Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
    Type: Application
    Filed: September 29, 2016
    Publication date: January 19, 2017
    Inventors: Frank S. CARUSO, Huai-Hung KAO
  • Publication number: 20170014406
    Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
    Type: Application
    Filed: September 29, 2016
    Publication date: January 19, 2017
    Inventors: Frank S. CARUSO, Huai-Hung Kao
  • Publication number: 20170014407
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, for use in the prevention or treatment of an ataxic disorder.
    Type: Application
    Filed: March 6, 2015
    Publication date: January 19, 2017
    Inventor: Sarah ALMOND
  • Publication number: 20170014408
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: July 13, 2016
    Publication date: January 19, 2017
    Inventors: Yao-Ling Qiu, Hui Cao, Wei Li, Xiaowen Peng, Meizhong Jin, Jorden Kass, Xuri Gao, Yat Sun Or
  • Publication number: 20170014409
    Abstract: The present disclosure relates to methods of treating inflammation in a subject. Particularly, the disclosure provides methods for treating inflammation by administering pharmaceutically active serelaxin in order to increase a soluble marker associated with reducing inflammation. Further encompassed in the present disclosure are method for treating inflammatory disorders and kits for administering pharmaceutically active serelaxin to subjects suffering from such disorders.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 19, 2017
    Inventor: Elaine Unemori
  • Publication number: 20170014410
    Abstract: Methods employing chemiluminescent agents as therapeutically active agents in the treatment of proliferative disorders are disclosed. The chemiluminescent agents are used in the disclosed method without a therapeutically effective amount of a photosensitizer. Novel chemiluminescent agents having the general formula: are also disclosed, wherein X, Y, Z, R3 and R5-R9 are as defined herein.
    Type: Application
    Filed: September 29, 2016
    Publication date: January 19, 2017
    Applicants: Semorex Technologies Ltd., Ariel-University Research and Development Company Ltd.
    Inventors: Bernard S. GREEN, Galia LUBOSHITS, Michael A. FIRER
  • Publication number: 20170014411
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.
    Type: Application
    Filed: June 9, 2016
    Publication date: January 19, 2017
    Applicant: Rexahn Pharmaceuticals, Inc.
    Inventors: Young Bok Lee, Deog Joong Kim, Reza Mazhari, Godefridus J. Peters, Dzjemma Sarkisjan
  • Publication number: 20170014412
    Abstract: A program for outpatient modified rapid detoxification for addiction to alcohol and drugs is disclosed. Patients are seen by trained medical professionals who are recovering addicts and alcoholics. The medication protocol addresses all of the withdrawal symptoms while allowing the patient to safely sleep through the detoxification.
    Type: Application
    Filed: July 15, 2016
    Publication date: January 19, 2017
    Inventors: David Alan Hall, Terry Lee Yeiter
  • Publication number: 20170014413
    Abstract: Novel RET fusion molecules and uses are disclosed. In one embodiment, a KIF5B-RET fusion includes an in-frame fusion of an exon of KIF5B (e.g., one or more exons encoding a kinesin motor domain or a fragment thereof) and an exon of RET (e.g., one or more exons encoding a RET tyrosine kinase domain or a fragment thereof). For example, the KIF5B-RET fusion can include an in-frame fusion of at least exon 15 of KIF5B or a fragment thereof (e.g., exons 1-15 of KIF5B or a fragment thereof) with at least exon 12 of RET or a fragment thereof (e.g., exons 12-20 of RET or a fragment thereof).
    Type: Application
    Filed: February 17, 2016
    Publication date: January 19, 2017
    Inventors: Sean R. Downing, Matthew J. Hawryluk, Doron Lipson, Alexander N. Parker, Philip James Stephens
  • Publication number: 20170014414
    Abstract: A pharmaceutical composition including trametinib or a pharmaceutically acceptable salt thereof as active ingredient and a carrier is described herein. Also described is an intermediate for the preparation of the pharmaceutical composition and a method of preparing the pharmaceutical composition or the intermediate.
    Type: Application
    Filed: February 24, 2015
    Publication date: January 19, 2017
    Applicant: ratiopharm GmbH
    Inventors: Dirk LEUTNER, Hans-Juergen MIKA, Jutta STROHMEYER
  • Publication number: 20170014415
    Abstract: The present invention provides for the design and synthesis of halogenated thieno- and pyrrolopyrimidine compounds that exhibit cancer proliferation inhibitory activity and the use thereof for cancer treatment.
    Type: Application
    Filed: August 29, 2016
    Publication date: January 19, 2017
    Inventors: KATHERINE L. RADTKE, KARTIK TEMBURNIKAR
  • Publication number: 20170014416
    Abstract: Compositions and methods for the treatment of a unipolar depression containing betaine, and folate. Formulations for oral administration optionally also contain L-methionine.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 19, 2017
    Inventor: Robert T. Dunn
  • Publication number: 20170014417
    Abstract: A pharmaceutical administration system for the transdermal application of at least one active agent includes vardenafil and/or a pharmaceutically acceptable salt thereof as the active agent and a pharmaceutically acceptable carrier providing a solution of the at least one active agent in the administration system. Another active agent may be testosterone. This system can be used to systemically deliver therapeutic doses of vardenafil and/or a pharmaceutically acceptable salt thereof and optionally testosterone in order to treat benign prostatic hyperplasia, erectile dysfunction, male hypogonadism, pulmonary hypertension, and/or pulmonary arterial hypertension.
    Type: Application
    Filed: July 14, 2015
    Publication date: January 19, 2017
    Applicant: LIPP LIFE SCIENCES LLC
    Inventor: Ralph LIPP